Header Logo

Connection

Heather Feigelson to Risk Factors

Back to Details
This is a "connection" page, showing publications Heather Feigelson has written about Risk Factors.
Heather Feigelson
Connection Strength
1.304
Risk Factors
  1. Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. J Cancer Surviv. 2017 Jun; 11(3):393-400.
    View in: PubMed
    Score: 0.084
  2. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.075
  3. Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PLoS One. 2014; 9(5):e94977.
    View in: PubMed
    Score: 0.070
  4. Feasibility of self-collection of fecal specimens by randomly sampled women for health-related studies of the gut microbiome. BMC Res Notes. 2014 Apr 01; 7:204.
    View in: PubMed
    Score: 0.069
  5. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg. 2013 May; 216(5):966-75.
    View in: PubMed
    Score: 0.064
  6. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet. 2010 Oct 01; 19(19):3873-84.
    View in: PubMed
    Score: 0.053
  7. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2553-7.
    View in: PubMed
    Score: 0.050
  8. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer. 2006 Jul 01; 107(1):12-21.
    View in: PubMed
    Score: 0.040
  9. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. J Natl Cancer Inst. 2024 Aug 01; 116(8):1384-1394.
    View in: PubMed
    Score: 0.035
  10. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):1084-5.
    View in: PubMed
    Score: 0.035
  11. Improving Care for Marginalized Populations at Risk for Hereditary Cancer Syndromes: Innovations that Expanded Reach in the CHARM Study. Public Health Genomics. 2024; 27(1):16-22.
    View in: PubMed
    Score: 0.034
  12. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort. Breast Cancer Res. 2023 05 03; 25(1):50.
    View in: PubMed
    Score: 0.032
  13. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):161-4.
    View in: PubMed
    Score: 0.032
  14. Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 2022 11; 23(11):1451-1464.
    View in: PubMed
    Score: 0.031
  15. Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis. 2002 Sep; 17(5):445-6; author reply 447-8.
    View in: PubMed
    Score: 0.031
  16. Alcohol consumption increases the risk of fatal breast cancer (United States). Cancer Causes Control. 2001 Dec; 12(10):895-902.
    View in: PubMed
    Score: 0.029
  17. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 2001 Jan 15; 61(2):785-9.
    View in: PubMed
    Score: 0.028
  18. Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res. 2000; 2(4):277-82.
    View in: PubMed
    Score: 0.026
  19. Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res. 1999 Aug 15; 59(16):3908-10.
    View in: PubMed
    Score: 0.025
  20. Re: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 1997 Dec 03; 89(23):1810-2.
    View in: PubMed
    Score: 0.022
  21. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
    View in: PubMed
    Score: 0.021
  22. Risk of Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women. Am J Epidemiol. 2017 02 15; 185(4):264-273.
    View in: PubMed
    Score: 0.021
  23. Estrogens and breast cancer. Carcinogenesis. 1996 Nov; 17(11):2279-84.
    View in: PubMed
    Score: 0.021
  24. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol. 2017 02 09; 3(2):186-193.
    View in: PubMed
    Score: 0.021
  25. Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. Breast Cancer Res Treat. 2016 Feb; 155(3):531-40.
    View in: PubMed
    Score: 0.020
  26. Socioeconomic Factors Affect Outcomes in Well-Differentiated Thyroid Cancer. Otolaryngol Head Neck Surg. 2016 Mar; 154(3):440-5.
    View in: PubMed
    Score: 0.019
  27. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013 Apr; 45(4):392-8, 398e1-2.
    View in: PubMed
    Score: 0.016
  28. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 05; 104(17):1293-305.
    View in: PubMed
    Score: 0.016
  29. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet. 2011 Aug 15; 20(16):3322-9.
    View in: PubMed
    Score: 0.014
  30. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet. 2011 Jul 15; 20(14):2869-78.
    View in: PubMed
    Score: 0.014
  31. Coronary disease and stroke in patients with large-vessel peripheral arterial disease. Drugs. 1991; 42 Suppl 5:16-21.
    View in: PubMed
    Score: 0.014
  32. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. Int J Cancer. 2010 Dec 15; 127(12):2928-35.
    View in: PubMed
    Score: 0.014
  33. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
    View in: PubMed
    Score: 0.013
  34. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010 Mar 18; 362(11):986-93.
    View in: PubMed
    Score: 0.013
  35. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2734-44.
    View in: PubMed
    Score: 0.013
  36. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet. 2009 Oct; 41(10):1055-7.
    View in: PubMed
    Score: 0.013
  37. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer. 2008 Oct 15; 123(8):1877-82.
    View in: PubMed
    Score: 0.012
  38. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008 Jul 02; 3(7):e2578.
    View in: PubMed
    Score: 0.012
  39. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):73-9.
    View in: PubMed
    Score: 0.011
  40. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007 Jul; 39(7):870-4.
    View in: PubMed
    Score: 0.011
  41. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007 May; 39(5):645-9.
    View in: PubMed
    Score: 0.011
  42. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007 Mar 01; 67(5):1893-7.
    View in: PubMed
    Score: 0.011
  43. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007; 9(1):R9.
    View in: PubMed
    Score: 0.010
  44. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2005 Dec; 14(12):2898-904.
    View in: PubMed
    Score: 0.010
  45. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet. 2005 Nov; 1(5):e68.
    View in: PubMed
    Score: 0.010
  46. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res. 2005; 7(6):R1168-73.
    View in: PubMed
    Score: 0.010
  47. Risk factors for fatal breast cancer in African-American women and White women in a large US prospective cohort. Am J Epidemiol. 2005 Oct 15; 162(8):734-42.
    View in: PubMed
    Score: 0.010
  48. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005 Jan; 14(1):261-4.
    View in: PubMed
    Score: 0.009
  49. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002 Sep; 11(9):795-800.
    View in: PubMed
    Score: 0.008
  50. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002 May 01; 94(9):2490-501.
    View in: PubMed
    Score: 0.008
  51. Jewish ethnicity and prostate cancer mortality in two large US cohorts. Cancer Causes Control. 2002 Apr; 13(3):271-7.
    View in: PubMed
    Score: 0.008
  52. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002 Jan 15; 94(2):500-11.
    View in: PubMed
    Score: 0.007
  53. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res. 2001 Feb 01; 61(3):848-9.
    View in: PubMed
    Score: 0.007
  54. Declining cancer rates in the 1990s. J Clin Oncol. 2000 Jun; 18(11):2258-68.
    View in: PubMed
    Score: 0.007
  55. IgE predicts future nonfatal myocardial infarction in men. J Clin Epidemiol. 1996 Feb; 49(2):203-9.
    View in: PubMed
    Score: 0.005

© 2024 Kaiser Permanente